HCA Healthcare - Q1 2026 Earnings Analysis

Performance Highlights

HCA Healthcare reported Q1 2026 revenues of $19.109 billion, up 4.3% year-over-year, beating consensus estimates alongside diluted EPS of $7.15 versus $6.45 in Q1 2025, a 10.9% increase driven partly by a lower effective tax rate of 18.8% versus 21.6% a year ago. Net income attributable to HCA reached $1.620 billion, while operating cash flow surged to $2.014 billion from $1.651 billion in Q1 2025, reflecting strong working capital management.

The primary revenue driver was a 3.1% increase in revenue per equivalent admission on both a consolidated and same-facility basis, complementing a 1.3% rise in same-facility equivalent admissions. Segment performance was mixed, with the National Group delivering the strongest EBITDA growth to $1.258 billion from $1.132 billion, while the Atlantic and American Groups were broadly stable at $1.439 billion and $1.414 billion, respectively.

Management Outlook and Forward Catalysts

Management flagged active monitoring of pending CMS approvals for state Medicaid directed payment programs, including Florida's program year beginning October 2024, which if approved could contribute materially to future revenues. The company also signaled its $10 billion January 2026 buyback authorization remains largely intact at $9.179 billion, underscoring confidence in capital return capacity and balance sheet flexibility despite $48.0 billion in total debt.

The central investor debate heading into Q2 2026 centres on whether HCA can sustain revenue per admission growth to absorb accelerating uninsured volume pressure, with same-facility uninsured admissions up 15.5% year-over-year and estimated uncompensated care costs rising to $1.252 billion from $1.055 billion. Bulls will focus on pricing power, cash generation, and potential Medicaid SDP upside, while bears watch Medicaid reform risk, surgical volume declines, and EPTC-driven payer-mix deterioration as the key earnings headwinds for the remainder of 2026.